Jorey Chernett Buys 105,848 Shares of AirSculpt Technologies (NASDAQ:AIRS) Stock

AirSculpt Technologies, Inc. (NASDAQ:AIRS) major shareholder Jorey Chernett purchased 105,848 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was bought at an average price of $2.43 per share, for a total transaction of $257,210.64. Following the purchase, the insider directly owned 6,592,059 shares in the company, valued at $16,018,703.37. The trade was a 1.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Jorey Chernett also recently made the following trade(s):

• On Wednesday, March 11th, Jorey Chernett bought 88,000 shares of AirSculpt Technologies stock. The stock was bought at an average cost of $2.15 per share, for a total transaction of $189,200.00.
• On Friday, March 6th, Jorey Chernett bought 45,600 shares of AirSculpt Technologies stock. The stock was bought at an average cost of $2.00 per share, for a total transaction of $91,200.00.
• On Wednesday, March 4th, Jorey Chernett bought 30,000 shares of AirSculpt Technologies stock. The stock was bought at an average cost of $1.87 per share, for a total transaction of $56,100.00.
• On Tuesday, March 3rd, Jorey Chernett purchased 80,000 shares of AirSculpt Technologies stock. The shares were bought at an average price of $1.71 per share, with a total value of $136,800.00.

AirSculpt Technologies Price Performance

AIRS opened at $2.69 on Wednesday. The firm has a market cap of $167.96 million, a PE ratio of -8.97 and a beta of 2.75. The stock has a 50-day moving average price of $2.24 and a 200-day moving average price of $4.63. AirSculpt Technologies, Inc. has a 1 year low of $1.51 and a 1 year high of $12.00. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.51 and a quick ratio of 0.51.

Institutional Trading of AirSculpt Technologies

Institutional investors have recently added to or reduced their stakes in the business. Citizens Financial Group Inc. RI raised its stake in shares of AirSculpt Technologies by 49.1% in the second quarter. Citizens Financial Group Inc. RI now owns 147,900 shares of the company’s stock worth $714,000 after purchasing an additional 48,734 shares during the last quarter. Centiva Capital LP purchased a new stake in shares of AirSculpt Technologies during the third quarter valued at $178,000. Larson Financial Group LLC boosted its position in shares of AirSculpt Technologies by 20.4% during the third quarter. Larson Financial Group LLC now owns 15,137 shares of the company’s stock valued at $121,000 after buying an additional 2,561 shares during the last quarter. Jane Street Group LLC bought a new stake in AirSculpt Technologies in the 2nd quarter worth about $60,000. Finally, Invesco Ltd. bought a new stake in AirSculpt Technologies in the 1st quarter worth about $56,000. 91.54% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about AirSculpt Technologies

Here are the key news stories impacting AirSculpt Technologies this week:

• Positive Sentiment: Major insider buying by Jorey Chernett (105,848 shares at ~$2.43) increases a meaningful insider stake, signaling management confidence and providing a potential floor for investor sentiment. Insider Buying: AirSculpt Technologies (NASDAQ:AIRS) Major Shareholder Purchases 105,848 Shares of Stock
• Positive Sentiment: Company reported preliminary FY2025 revenue of $151.8M and says a refreshed marketing strategy produced positive same‑store sales in February; management expects Q1 2026 same‑store revenue roughly flat at the midpoint — supportive for near‑term demand recovery expectations. AirSculpt Technologies (AIRS) Is Up 36.2% After Guiding To Flatter Same-Store Revenue Trends
• Neutral Sentiment: Unusual options activity: a large spike in call buying (11,531 calls, ~933% above normal) indicates speculative or hedged bullish interest but does not confirm sustained directional conviction.
• Neutral Sentiment: Short-interest reports in the data feed show zero reported short shares (with inconsistent/NaN changes), which appears unreliable and is not currently informative about true short positioning.
• Negative Sentiment: MarketWatch notes the stock fell on an expected Q4 revenue decline — investors are focusing on quarter‑end softness (Q4 same‑store revenue down ~16%) and potential downward revisions to near‑term growth. AirSculpt Technologies Falls on Expected 4Q Revenue Decline
• Negative Sentiment: AirSculpt filed a Form 12b‑25 to delay its annual 10‑K to finalize inter‑company classifications — raises short‑term transparency and timing risk. The company also reported $13.0M cash vs. $46.0M debt, highlighting liquidity and leverage concerns that could pressure the stock if results or cash flow weaken. AirSculpt Technologies Announces Its Intent to Delay the Filing of its Annual Report and Provides Business Update

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of AirSculpt Technologies in a research note on Monday, December 29th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, AirSculpt Technologies has an average rating of “Reduce” and an average price target of $6.00.

AirSculpt Technologies Company Profile

AirSculpt Technologies, Inc (NASDAQ: AIRS) is a medical technology company specializing in minimally invasive body contouring. The company’s flagship AirSculpt® platform combines pneumatic power with precision microcannulas to deliver fat removal, transfer and sculpting procedures. AirSculpt Technologies partners with both company-owned and franchised cosmetic surgery practices to offer a streamlined, office-based alternative to traditional liposuction.

Through its proprietary system, AirSculpt Technologies provides both consumers and medical professionals with an integrated solution that emphasizes reduced downtime, smaller incision sites, and more predictable outcomes.